Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05216354 · ClinicalTrials.gov registry record · Phase 1
Fruquintinib Renal Impairment Study
A Phase 1 study of Renal Impairment, sponsored by Hutchmed.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT05216354: Completed Phase 1 study of Renal Impairment, sponsored by Hutchmed.
NCT05216354 is a Phase 1 study of Renal Impairment that has completed, run by Hutchmed. The registered enrollment target is 24 participants, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (29% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05216354, a Phase 1 study of Renal Impairment, has completed, sponsored by Hutchmed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
A multicenter, open label, single-dose, single-period, sequential study to assess the effect of renal impairment on the pharmacokinetics of Fruquintinib
Primary Outcome
Area under the plasma concentration-time curve from time 0 to time of the last measurable concentration
Conditions Studied
Interventions
- DRUG Fruquintinib
Study Locations (2)
Florida
- Clinical Pharmacology of Miami - Miami
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-03-11 |
| Est. Completion | 2023-06-26 |
| Phase | Phase 1 |
What the finished NCT05216354 record still lists
NCT05216354 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which Fruquintinib is the first listed.
NCT05216354 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05216354 about?
NCT05216354 is a clinical study titled "Fruquintinib Renal Impairment Study". A multicenter, open label, single-dose, single-period, sequential study to assess the effect of renal impairment on the pharmacokinetics of Fruquintinib
What is the current status of trial NCT05216354?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-03-11. Estimated completion is 2023-06-26.
What conditions does trial NCT05216354 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT05216354?
The interventions under investigation include: Fruquintinib (DRUG).
Who is sponsoring clinical trial NCT05216354?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05216354 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05216354's enrollment target sits among peer trials
24 23rd of 32 higher than 9 of 32 other Renal Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI